Upgrade to SI Premium - Free Trial

Seattle Genetics (SGEN) Reports First Patient Dosed in Phase 2 innovaTV 207 Trial Evaluating Tisotumab Vedotin in Multiple Solid Tumors

July 12, 2018 8:01 AM
Seattle Genetics, Inc. (NASDAQ: SGEN) today announced dosing of the first patient in the phase 2 innovaTV 207 clinical trial ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

FDA Management Comments

Next Articles